Erythropoietic protoporphyria: time to prodrome, the warning signal to exit sun exposure without pain—a patient-reported outcome efficacy measure

Purpose Patients with erythropoietic protoporphyria (EPP), a severe painful photodermatosis, experience prodromal sensations when exposed to sunlight, which are the “warning signals” to exit the sun, as prolonged exposure causes an excruciatingly painful phototoxic attack. The unique prodromal cutan...

Full description

Saved in:
Bibliographic Details
Published in:Genetics in medicine 2021-09, Vol.23 (9), p.1616-1623
Main Authors: Wensink, D., Langendonk, J. G., Overbey, J. R., Balwani, M., Van Broekhoven, E. J. E., Wagenmakers, M. A. E. M., Wilson, J. H. P., Wheeden, K., Naik, H., Desnick, R. J.
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Clinical trials
Disease
Endothelium
Human Genetics
Humans
Laboratory Medicine
Light
Medicine
Metabolism
Pain
Patient Reported Outcome Measures
Patients
Protoporphyria, Erythropoietic - diagnosis
Protoporphyria, Erythropoietic - drug therapy
Quality of life
Retrospective Studies
Sun
Sunlight - adverse effects
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Patients with erythropoietic protoporphyria (EPP), a severe painful photodermatosis, experience prodromal sensations when exposed to sunlight, which are the “warning signals” to exit the sun, as prolonged exposure causes an excruciatingly painful phototoxic attack. The unique prodromal cutaneous sensations are reversible and differ from the severe burning pain attack lasting 2–7 days. Previously, afamelanotide treatment was studied using time to pain or time outside as primary outcome measures. Since patients have an ingrained fear of sunlight, these measures did not capture the full treatment effect. We retrospectively characterized and evaluated time to prodrome (TTP) as a safer, patient-reported outcome (PRO) measure in afamelanotide-treated patients. Methods Structured interviews recorded TTP before and during afamelanotide treatment in retrospective US and Dutch cohort studies. Results Thirty-one US and 58 Dutch EPP patients participated. Before afamelanotide treatment, 54.8% US and 39.7% Dutch patients reported TTP onset
ISSN:1098-3600
1530-0366
DOI:10.1038/s41436-021-01176-z